GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » EV-to-FCF

Revive Therapeutics (XCNQ:RVV) EV-to-FCF : -6.10 (As of May. 20, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Revive Therapeutics's Enterprise Value is C$8.41 Mil. Revive Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.38 Mil. Therefore, Revive Therapeutics's EV-to-FCF for today is -6.10.

The historical rank and industry rank for Revive Therapeutics's EV-to-FCF or its related term are showing as below:

XCNQ:RVV' s EV-to-FCF Range Over the Past 10 Years
Min: -14.6   Med: 0   Max: 0
Current: -6.1

XCNQ:RVV's EV-to-FCF is ranked worse than
100% of 520 companies
in the Drug Manufacturers industry
Industry Median: 25.045 vs XCNQ:RVV: -6.10

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-20), Revive Therapeutics's stock price is C$0.025. Revive Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.003. Therefore, Revive Therapeutics's PE Ratio for today is At Loss.


Revive Therapeutics EV-to-FCF Historical Data

The historical data trend for Revive Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics EV-to-FCF Chart

Revive Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.71 -22.64 -15.16 -11.05 -2.36

Revive Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.49 -4.14 -2.36 -9.40 -7.40

Competitive Comparison of Revive Therapeutics's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revive Therapeutics's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's EV-to-FCF falls into.



Revive Therapeutics EV-to-FCF Calculation

Revive Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8.409/-1.379
=-6.10

Revive Therapeutics's current Enterprise Value is C$8.41 Mil.
Revive Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revive Therapeutics  (XCNQ:RVV) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Revive Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.025/-0.003
=At Loss

Revive Therapeutics's share price for today is C$0.025.
Revive Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.003.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Revive Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics (XCNQ:RVV) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
Executives
Michael Frank Director, Senior Officer

Revive Therapeutics (XCNQ:RVV) Headlines

No Headlines